TriOar Inc. has raised $24.6M in Series C funding to push forward its work on next-generation antibody-based cancer therapies. The company is focused on antibody-drug conjugates and immuno-oncology technologies.
TriOar's stated goal is expanding the therapeutic index - widening the gap between a drug's benefit and its toxicity - so that more patients can benefit from novel cancer treatments. The company says its team is made up of experienced scientists in the field.
















